Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Haig Tcheurekdjian

Allergy & Immunology Mayfield Heights, OH Medical Doctor

NPI 1992724843 CMS profile 271595

5915 Landerbrook Dr, Ste. 110, Mayfield Heights, OH 44124

Open in the dashboard

General payments

$4,863

371 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Haig Tcheurekdjian of Mayfield Heights, OH is reported in the CMS Open Payments database as having received $4,863 across 371 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 56th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $331 16
2024 General $816 46
2023 General $818 65
2022 General $814 64
2021 General $884 65
2020 General $429 39
2019 General $769 76

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Haig Tcheurekdjian
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Haig Tcheurekdjian were reported at $331. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Haig Tcheurekdjian Allergy & Immunology median Middle half National median
2019 $769 $594 $163–$1,512 $163
2020 $429 $426 $106–$1,233 $114
2021 $884 $638 $157–$1,708 $132
2022 $814 $790 $205–$1,961 $149
2023 $818 $852 $220–$2,147 $160
2024 $816 $865 $203–$2,267 $164
2025 $331 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $1,589 197 payments
  2. Novartis Pharmaceuticals Corporation $1,301 65 payments
  3. AbbVie, Inc. $394 19 payments
  4. Pfizer Inc. $190 9 payments
  5. ADMA BioManufacturing LLC $165 14 payments
  6. Octapharma USA, Inc. $141 7 payments
  7. Amgen Inc. $130 6 payments
  8. Genentech USA, Inc. $129 8 payments
  9. GC Biopharma USA, Inc. $101 5 payments
  10. Teva Pharmaceuticals USA, Inc. $82 5 payments
  11. Other $640 36 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,775 363 payments
  2. Consulting Fee $88 8 payments
Products named General payments · program years 2019–2025
  1. NUCALA Immunology $836 108 payments
  2. XOLAIR Respiratory $719 38 payments
  3. XOLAIR Pulmonary/Respiratory Diseases $502 22 payments
  4. NUCALA Respiratory $412 64 payments
  5. TRELEGY ELLIPTA $314 23 payments
  6. UBRELVY $234 12 payments
  7. QULIPTA $145 6 payments
  8. CUTAQUIG $139 6 payments
  9. PANZYGA $139 6 payments
  10. Xolair Immunology $129 8 payments
  11. Other $1,468 80 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 40 drugs

Part D claims

1,264

Median for Allergy/ Immunology: 449

Drug cost

$318,162

Median for Allergy/ Immunology: $169,700

Branded share of claims

39.9%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Syringe Dupilumab Brand 23 $108,532
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 110 $84,900
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 15 $21,951
Spiriva Respimat Tiotropium Bromide Brand 32 $15,742
Epinephrine Generic 34 $14,380
Dulera Mometasone/Formoterol Brand 23 $11,741
Breo Ellipta Fluticasone/Vilanterol Brand 22 $8,408
Symbicort Budesonide/Formoterol Fumarate Brand 20 $7,580
Arnuity Ellipta Fluticasone Furoate Brand 27 $6,652
Azelastine Hcl Generic 181 $6,050

The 10 drugs with the highest cost, of 40 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$4,704,853

Of which drugs: $4,550,529

Medicare patients

208

Average age 74

Services billed

83,240

164 women, 44 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 58%
High blood pressure 57%
Osteoporosis 30%
Depression 28%
COPD 26%
Ischemic heart disease 18%
Chronic kidney disease 18%
Diabetes 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, immune globulin (bivigam), 500 mg J1556 Office 31 37,067 $2,151,765
Injection, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2 exposure, and who either have moderate-to-severe immune compromise due to a medica Q0224 Office 27 41 $264,525
Vaccine for influenza for injection into muscle 90653 Office 35 35 $2,861
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 20 1,652 $372

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUCALA
  • GlaxoSmithKline, LLC. $270
$270 — —
XOLAIR
  • Novartis Pharmaceuticals Corporation $233
$233 — —
TEZSPIRE
  • Amgen Inc. $55
  • AstraZeneca Pharmaceuticals LP $23
$79 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $36
$36 110 —
UBRELVY
  • AbbVie, Inc. $31
$31 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

371 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record